Technical

The Price Picture

The fundamentals are mid-single-digit margins on 60%+ growth; the chart is a stock that ran from $8 to $73 in twelve months and gave back two-thirds of that gain in the next twelve. Today HIMS sits 24% below its 200-day average with a death cross fired in December 2025, but the last month has been a vertical bounce — +29% in 30 days, +19% in the past week, with MACD now firmly above its signal line. The price action confirms what the Numbers tab flagged on margins: the structural reset is real and ongoing. The open question on the chart is whether the current bounce is the start of a new uptrend or a relief rally inside a broken one.

Snapshot

Trend — price vs the 200-day, full lifetime view

The chart shows three regimes since IPO: the long sleep from late-2021 through 2023 (price under $10, both averages flat), the historic 9× run from January 2024 to February 2025, and the rolling top that's now resolved into a clear downtrend. Price ($29.01) is currently 24% below the 200-day SMA ($38.10). This is a downtrend, full stop — the bounce off the February low has only carried price back to the 50-day, not above it.

Relative strength — still a winner over three years, but the gap is closing

Over three years HIMS is still up 164% versus the S&P 500 and 154% versus the XLV healthcare ETF on a relative basis — that is a massive lead. But the gap has been closing since the February 2025 peak (where HIMS hit 532 vs SPY's 148), and the 12-month line is now sloping the wrong way: from a relative high near 555 in May 2025 the index is back at 264 today, while SPY has continued grinding higher to 172. HIMS still wins the three-year race; it has been losing the twelve-month one.

Momentum — RSI and MACD say the bounce has teeth (for now)

RSI just printed 67 after touching 15 in mid-February — a 50-point swing in two months, one of the more violent momentum reversals you can find on a $6B-cap stock. The MACD histogram has flipped from deeply negative (-1.0 in early Feb) to firmly positive (+1.1), confirming the move. Near-term, this is bullish. But note the asymmetry: every prior MACD spike above +1.5 in the past 18 months (May 2025, Feb 2025) was followed within weeks by a sharp negative reversal. Momentum here travels in both directions fast.

Volume & conviction

The 50-day average has fallen from a frothy 52M shares/day in mid-2025 to under 20M by year-end, then jumped back to ~40M as the recent volatility returned. Two of the three biggest panic prints in the past year are negative-return capitulation days (Jun 23, 2025 and Feb 9, 2026); the third (Mar 9, 2026) is a +41% rip on similar volume — classic sign of forced positioning unwinding both ways. The current bounce is happening on rising volume, which is constructive, but it's roughly half the conviction of the May 2025 surge that ultimately failed.

Volatility regime — stressed, and back at the high end

Realized 30-day volatility sits at 96%, just above the 10-year 80th-percentile threshold (92%) — the market is pricing this stock in the "stressed" regime. For perspective: the median realized vol over the past five years is 63%; today's reading is half-again above that. The market is treating every print as a potential 30%+ day, and the data backs it up — five separate single-day moves above ±15% in the past twelve months alone.

Technical scorecard

Stance — neutral, with a tight bias to bearish on a 3-to-6 month horizon

The long-term trend is broken (sub-200d, recent death cross, six-month return of −44%) and volatility is in a stressed regime — both arguments against a clean bottom call here. But the near-term momentum reset has been violent and unmistakable: RSI from 15 to 67, MACD flipped, price up 29% in 30 days on rising volume. This is the signature of either the start of a base-build or a powerful relief rally — and the chart cannot distinguish the two until price proves itself against the 200-day.

The two levels that resolve it:

Above $38 — reclaim of the 200-day SMA — would invalidate the downtrend, restore a bullish posture, and align the chart with a "GLP-1 reset already discounted" thesis. Below $20 — break of the 50-day SMA and the recent April swing low — would confirm the death cross, target the $14 February low, and align with the Numbers tab's gross-margin warning that the worst is not yet priced.

The price action confirms the Numbers-tab concern that gross-margin compression is structural, not transitional: the $73-to-$14 round-trip began the same week management guided to the new margin reality. Until price reclaims the 200-day, the market's verdict is that the $73 high was a euphoria peak and the work of rebuilding is still ahead.